Boston Scientific Corp (BSX)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 2,587,000 | 2,257,000 | 1,605,000 | 1,425,000 | 389,000 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 21,770,000 | 19,282,000 | 17,574,000 | 16,623,000 | 15,327,000 |
| Return on total capital | 11.88% | 11.71% | 9.13% | 8.57% | 2.54% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $2,587,000K ÷ ($—K + $21,770,000K)
= 11.88%
Boston Scientific Corp's return on total capital has shown a positive trend over the past five years. Starting at 2.54% on December 31, 2020, it has steadily increased to 11.88% by December 31, 2024. This indicates that the company has been effectively utilizing its capital to generate returns for its investors. The consistent growth in return on total capital suggests improved operational efficiency and profitability in the business, reflecting positively on the company's overall financial performance over the years.
Peer comparison
Dec 31, 2024
Company name
Symbol
Return on total capital
Boston Scientific Corp
BSX
11.88%
3M Company
MMM
32.22%
Artivion Inc
AORT
9.69%
Baxter International Inc
BAX
-1.75%
Becton Dickinson and Company
BDX
5.78%
DexCom Inc
DXCM
29.63%
Embecta Corp
EMBC
20.17%
Glaukos Corp
GKOS
-15.96%
Globus Medical
GMED
5.26%
Haemonetics Corporation
HAE
9.38%
ICU Medical Inc
ICUI
2.06%